Contrast Enhanced Ultrasound Market Size, Share, and Industry Analysis, By Product (Equipment and Contrast Agents), By Application (Cardiovascular Imaging, Abdominal Imaging, Renal & Urological Imaging, Obstetrics & Gynecology, and Others), By End-user (Hospitals & ASCs, Diagnostic Imaging Centers, and Others), and Regional Forecast, 2026-2034

The contrast enhanced ultrasound market size was valued at USD 2.26 billion in 2025 and is expected to reach a market valuation of USD 2.41 billion in 2026. Furthermore, the market is projected to reach a market valuation of USD 4.01 billion by 2034, exhibiting a CAGR of 6.6% during the forecast period.

In several developed countries, multi-society guidance has progressively standardized the performance and interpretation of contrast-enhanced ultrasound (CEUS) in the liver to reduce variability and increase clinician confidence. As a result, hospitals and imaging centers are more willing to invest in training and routine use, expanding exam volumes and contrast agent consumption, driving the market growth.

Contrast Enhanced Ultrasound Market Driver

Expanding Access and Utilization Through Reimbursement Boosts the Market Growth

In recent years, there has been increased access to CEUS due to enhanced reimbursement, such as Medicare’s outpatient payment increase for non-cardiac CEUS. This is expected to directly increase providers' willingness to schedule CEUS exams and invest in contrast-capable workflows, supporting overall volume growth and market expansion.

• For instance, in January 2026, CMS doubled non-cardiac contrast-enhanced ultrasound (CEUS) reimbursement to USD 358.35 from USD 170.02 via billing code APC 5572, aligning with contrast CT/MR payments.

Download Free sample to learn more about this report.

According to data published in the RadNet Inc. Investor Day Presentation 2025, there were 405 total RadNet Inc.s operated imaging centers across the U.S.

Contrast Enhanced Ultrasound Market Restraint

Shortage of Skilled Workforce to Restrict the Market Growth

Despite the higher demand for contrast enhanced ultrasound, the dearth of a skilled workforce is posing a challenge to fulfill the demand for rising procedure volume, thereby declining or delaying the procedures. Also, limited enrollment in such training is expected further to limit access to care and hamper market growth.

• For instance, December 2022 data from the Association of American Medical Colleges (AAMC), as reported by the MICA, projects a shortage of nearly 42,000 radiologists and other clinical specialists in the U.S. by 2033.

Contrast Enhanced Ultrasound Market Opportunity

AI and Automation to Improve Reproducibility and Quantification

An artificial intelligence (AI)-driven image optimization and automated measurements reduce user dependency and make CEUS easier to execute consistently, which makes it favorable for community hospitals and imaging centers. This presents a significant opportunity for key players to update the features of their products, contributing to market expansion.

• For instance, in February 2025, Koninklijke Philips N.V. announced the introduction of CEUS-focused optimization features, such as “CEUS AutoScan,” and broader AI workflow enhancements.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Key Diseases, by Key Countries/Region, 2025
• Number of Ultrasound Procedures, by Key Countries/Region,2025
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Product

In terms of product, the market is segmented into equipment and contrast agents.

The equipment segment is expected to hold the major share of the global market during the forecast period. The growth is driven by system upgrades for supporting contrast imaging rather than greenfield installations, as most hospitals already own ultrasound platforms.

• For instance, in September 2023, Koninklijke Philips N.V. launched Microvascular Imaging Super Resolution CEUS on its EPIQ Elite ultrasound system, delivering up to 200.0% better spatial resolution using safe micro-bubble contrast for enhanced lesion blood flow assessment in cancer patients.

Analysis by Application

In terms of application, the market is segmented into cardiovascular imaging, abdominal imaging, renal & urological imaging, obstetrics & gynecology, and others.

The abdominal imaging segment is expected to hold the major share of the global market during the forecast period. The growth is attributed to the widespread use of CEUS to differentiate benign from malignant focal liver lesions, assess treatment response, and support surveillance in patients with chronic liver disease.

Analysis by End-user

Based on end-user, the market is divided into hospitals & ASCs, diagnostic imaging centers, and others.

The hospital & ASCs segment is expected to hold the largest share of the global market during the forecast period. The segment's growth is attributed to trained personnel, robust contrast administration infrastructure, and high patient volumes in these settings. Moreover, favorable reimbursement and the integration of CEUS into diagnostic pathways are expected to contribute to the segment’s growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 36.9% share of the global contrast enhanced ultrasound market in 2025. The region's growth is attributed to a well-established network of diagnostic imaging centers and radiologists, which has contributed to high adoption of CEUS.

• For instance, in June 2025, Medicus Healthcare Solutions, LLC mentioned that there are approximately 41,000 radiologists in the U.S.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth is attributed to a higher patient pool and expanding healthcare infrastructure in key countries such as India, China, South Korea, and more, which is favoring the adoption of contrast enhanced ultrasound in the region.

Key Players Covered

The global contrast enhanced ultrasound market is highly competitive, with key companies focusing on product upgrades and signing strategic deals with healthcare facilities to expand their product presence.

The report includes the profiles of the following key players:

• Bracco Diagnostics Inc. (U.S.)
• GE HealthCare (U.S.)
• Siemens Healthineers (Germany)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)
• Koninklijke Philips N.V. (Netherlands)
• Samsung Healthcare (South Korea)
• Esaote SPA (Italy)
• FUJIFILM Sonosite, Inc. (U.S.)
• TOMTEC IMAGING SYSTEMS GMBH (Germany)

Key Industry Developments

• August 2025: Koninklijke Philips N.V. launched Transcend Plus for EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems, featuring FDA-cleared 2D/3D image enhancements and 26 AI applications, including a new 2D Auto EF Advanced mode for sharper cardiac visualization and automated LV function assessment.
• May 2025: GE HealthCare received FDA approval for a pediatric indication for Optison (perflutren protein-type A microspheres), its ultrasound-enhancing agent.